FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to chemical and pharmaceutical industry and represents application of compound, selected from group, including 3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]piridin-1-yl}phenyl)ethyl]-1-[(4-methylebenzene)sulphonyl]urea; 4-((1S)-1-{[5-chloro-2-(4-fluorophenoxy)benzoyl]amino}ethyl)-benzoic acid and 4-[(1S)-1-({[5-chloro-2-(3-fluorophenoxy)piridin-3-yl]carbonyl}amino)ethyl]benzoic acid, or its pharmaceutically acceptable salt for production of medication for production of cancer dimensions, associated with prostaglandin E2 (PGE2) (for instance, gastroenterologic cancer, prostate cancer, lung cancer and breast cancer) in humans or animals.
EFFECT: obtaining pharmaceutically acceptable salt for production of medication for reduction of cancer dimensions.
5 cl, 5 dwg, 9 ex
